Olympus lands FDA de Novo approval for benign hyperplasia device
Olympus (TYO:7733) announced today that it received FDA de Novo classification for its iTind non-surgical device […]
Olympus (TYO:7733) announced today that it received FDA de Novo classification for its iTind non-surgical device for treating benign prostatic hyperplasia (BPH).
Israel-based medical device manufacturer Medi-Tate originally designed the iTind device. Olympus holds the exclusive right to distribute Medi-Tate products in the U.S. through a strategic investment.
The iTind is designed as a flexible, three-strut nitinol device that can be placed during an in-office procedure. It expands over five days to create channels for allowing urine to flow and reshaping the prostate. Medi-Tate’s device won CE Mark approval in Europe in 2012.
In a news release, certified urologist at New York’s University Urology Dr. Jed Kaminetsky said the office-based procedure can treat men who are suffering from common symptoms of an enlarged prostate and want a solution that has not been shown to compromise sexual function.
Added Medi-Tate founder & CEO Ido Kilemnik: “After over a decade in development and clinical trials, we are proud to bring this innovative and truly minimally invasive technology to the U.S. market.”
Original Article: (https://www.massdevice.com/olympus-lands-fda-de-novo-approval-for-benign-hyperplasia-device/)